Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C50H86O35P4 |
| Molecular Weight | 1371.0919 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCO[C@@H]1[C@H](OC(=O)CCC)[C@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@H](OP(=O)(OCOC(=O)CC)OCOC(=O)CC)[C@H]1OP(=O)(OCOC(=O)CC)OCOC(=O)CC
InChI
InChIKey=SVJGGWZOTSJMCQ-RMTIMQEASA-N
InChI=1S/C50H86O35P4/c1-11-21-22-23-24-25-27-64-45-46(81-44(59)26-12-2)48(83-87(61,75-30-67-38(53)15-5)76-31-68-39(54)16-6)50(85-89(63,79-34-71-42(57)19-9)80-35-72-43(58)20-10)49(84-88(62,77-32-69-40(55)17-7)78-33-70-41(56)18-8)47(45)82-86(60,73-28-65-36(51)13-3)74-29-66-37(52)14-4/h45-50H,11-35H2,1-10H3/t45-,46+,47+,48+,49-,50-/m1/s1
INO-4995, a synthetic analog of the intracellular signaling molecule, D-myo-inositol 3,4,5,6-tetrakisphosphate, regulates airway secretory and absorptive processes, affecting mucosal hydration by prolonged inhibition of Na(+) and fluid absorption in cystic fibrosis (CF) human nasal epithelia. At the moment INO-4995 is in preclinical development for CF treatment.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
169003
Created by
admin on Sat Dec 16 05:31:56 GMT 2023 , Edited by admin on Sat Dec 16 05:31:56 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10148804
Created by
admin on Sat Dec 16 05:31:56 GMT 2023 , Edited by admin on Sat Dec 16 05:31:56 GMT 2023
|
PRIMARY | |||
|
3LM5SX2N4X
Created by
admin on Sat Dec 16 05:31:56 GMT 2023 , Edited by admin on Sat Dec 16 05:31:56 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
